|49398T||1 Kit (8 x 20 microliters)||
|Claudin-1 (D3H7C) Rabbit mAb 13995||20 µl||
|E-Cadherin (24E10) Rabbit mAb 3195||20 µl||
||H M||135||Rabbit IgG|
|N-Cadherin (D4R1H) XP® Rabbit mAb 13116||20 µl||
||H M||140||Rabbit IgG|
|Slug (C19G7) Rabbit mAb 9585||20 µl||
||H M||30||Rabbit IgG|
|TWIST1 (E7E2G) Rabbit mAb (IF Formulated) 31174||20 µl||
||H M||Rabbit IgG|
|Vimentin (D21H3) XP® Rabbit mAb 5741||20 µl||
||H M R Mk||57||Rabbit IgG|
|ZEB1 (E2G6Y) XP® Rabbit mAb 70512||20 µl||
||H M R||200||Rabbit IgG|
|ZO-1 (D6L1E) Rabbit mAb 13663||20 µl||
||H Mk||220||Rabbit IgG|
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro194 of human claudin-1 protein, Pro780 of human E-cadherin protein, Arg526 of human N-cadherin protein, Pro24 of human TWIST1 protein, Arg45 of human vimentin protein, or Ala1558 of human ZO-1 protein. Monoclonal antibodies are produced by immunizing animals with a recombinant protein corresponding to human Slug protein or the central region of human ZEB1 protein.
Epithelial-mesenchymal transition (EMT) is an essential process during development whereby epithelial cells acquire mesenchymal, fibroblast-like properties and display reduced intracellular adhesion and increased motility. This is a critical feature of normal embryonic development, which is also utilized by malignant epithelial tumors to spread beyond their origin (1-3). This tightly regulated process is associated with a number of cellular and molecular events. EMT depends on a reduction in expression of cell adhesion molecules. Cadherins mediate calcium-dependent cell-cell adhesion and play critical roles in normal tissue development (4). E-cadherin is considered an active suppressor of invasion and growth of many epithelial cancers (4-6). Recent studies indicate that cancer cells have upregulated N-cadherin in addition to loss of E-cadherin. This change in cadherin expression is called the "cadherin switch" and downregulation of E-cadherin is one of the hallmarks of EMT (1). Tight junctions, or zonula occludens, form a continuous barrier to fluids across the epithelium and endothelium. They function in regulation of paracellular permeability and in the maintenance of cell polarity, blocking the movement of transmembrane proteins between the apical and the basolateral cell surfaces. Tight junctions are composed of claudin and occludin proteins, which join the junctions to the cytoskeleton (7,8). Zona occludens (ZO) proteins (e.g., ZO-1) are peripheral membrane adaptor proteins that link junctional transmembrane proteins such as occludin and claudin to the actin cytoskeleton (9). ZO proteins are required for tight junction formation and function (10,11); mutations in ZO-1 and claudin induce EMT (12). Vimentin is an intermediate filament of mesenchymal origin and is present at early developmental stages. Vimentin's dynamic structural changes and spatial re-organization in response to extracellular stimuli helps to coordinate various signaling pathways (13). Slug (SNAI2) is a widely expressed transcriptional repressor and member of the Snail family of zinc finger transcription factors (14,15). Similar to the related Snail protein, Slug binds to the E-cadherin promoter region to repress transcription during development (16). The binding of Slug to integrin promoter sequences represses integrin expression and results in reduced cell adhesion (17). ZEB family proteins (e.g., ZEB1) are zinc finger and homeobox domain containing transcription factors, whose targets of regulation include E-cadherin (1). TWIST1 is a basic helix-loop-helix (b-HLH) transcription factor that functions as a master regulator of embryonic morphogenesis, and plays essential roles in mesenchymal differentiation (18,19). TWIST is upregulated in various human tumors and has been suggested to be a driver of EMT and metastasis (20-21).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.